About

The Israeli multinational pharmaceutical company Teva Pharmaceuticals recently solidified its position as the leading generic drug manufacturer in the world by completing the acquisition of Actavis Generics (the generic drug business of Allergan). The company’s Polish subsidiary is now a leading player in the local drug and dietary market, operating a portfolio of medical products which include: specialised drugs, generic drugs and active pharmaceutical ingredients. A lawyer with vast regulatory and intellectual property expertise, Mirosław Zapała keeps up to date with relevant developments in the sector to protect Teva’s existing portfolio and to push new products in the local market. Despite widespread ethical problems on the global pharmaceutical market, Teva’s Polish subsidiary has ensured high standards of business ethics and compliance with applicable laws, a goal largely attributed to Zapała and his team. Prior to taking the helm of the legal department nearly 12 years ago, Zapała led the Polish legal department of the largest Croatian pharmaceutical company PLIVA.